08 Nov 2018
After two years of strong performance, Pacific Horizon (PHI) has suffered a reversal of fortune over the last three months. Sentiment swung against both China and the technology sector, with savage share price falls in some areas. However, this reversal of fortune may prove to be short-lived if China and the US can agree a […]
07 Nov 2018
Sareum Holdings – TYKing the boxes Sareum’s investment case centres on the development of the Chk1 inhibitor, SRA737, in solid tumours, by its licensee and on the internal development and potential licensing of internally-generated TYK2 candidates for autoimmune disease and cancer. Marten & Co values Sareum’s 27.5% economic interest in the licensing deal covering SRA737 […]